Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

PD 134308

Known as: PD-134308, PD134308 
National Institutes of Health

Related topics

Related topics

7 relations

Broader (5)

Anti-Anxiety AgentsAntineoplastic AgentsHormone AntagonistsIndoles
Expand
CI 988analogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2001
2001
Functional neuroanatomy of the ventral striopallidal GABA pathway New sites of intervention in the treatment of schizophrenia
  • W. O'Connor
  • Journal of Neuroscience Methods
  • 2001
  • Corpus ID: 6999706
Microdialysis was employed to investigate the dopamine, cholecystokinin (CCK) and neurotensin receptor regulation of ventral… 
1996
1996
Evidence for a differential cholecystokinin-B and -A receptor regulation of gaba release in the rat nucleus accumbens mediated via dopaminergic and cholinergic mechanisms
In the present study we characterized the cholecystokinin receptor regulation of (i) the dopamine D2 agonist binding sites in… 
1992
1992
CCK modulates inhibitory synaptic transmission in the solitary complex through CCKB sites.
The CCKB antagonists L-365, 260 and PD134308 and the CCKA antagonist L-364, 718 were applied to neurones of the rat solitary… 
Highly Cited
1991
Highly Cited
1991
Anxiolytic effects of CCK-B antagonists
PD134308 and PD135158 are highly selective CCK-B receptor antagonists and were used to investigate the role of CCK-B receptors in… 
Highly Cited
1991
Highly Cited
1991
Evaluation of the effects of PD 134308 (CI-988), A CCK-B antagonist, on the punished responding of squirrel monkeys
Lever pressing of squirrel monkeys was maintained by a fixed-interval 3-min schedule of food presentation during which every 30th… 
Highly Cited
1991
Highly Cited
1991
Evidence for an involvement of the brain cholecystokinin B receptor in anxiety.
The effect of neuropeptide cholecystokinin (CCK) receptor agonists and antagonists was examined in the rat elevated X-maze model… 
1991
1991
Development of CCK-B antagonists
Our approach to design small molecule non-peptide analogues of the neuropeptide cholecystokinin (CCK) has led to the discovery of… 
1991
1991
Inhibition of food intake by omeprazole in the chicken.
Chickens treated with the H+/K+ ATPase inhibitor omeprazole, to inhibit gastric acid secretion, failed to gain weight and showed… 
Highly Cited
1990
Highly Cited
1990
Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity.
PD134308 and PD135158 are potent and selective antagonists at the cholecystokinin type B (CCK-B) receptors with IC50 values of 1… 
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Highly Cited
1990
Highly Cited
1990
PD134308, a selective antagonist of cholecystokinin type B receptor, enhances the analgesic effect of morphine and synergistically interacts with intrathecal galanin to depress spinal nociceptive…
The effects of systemic PD134308 [0.1-3 mg/kg; an antagonist of the cholecystokinin (CCK) type B receptor], morphine, and… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE